Market Overview - The average daily trading volume in the A-share market decreased to 2.0 trillion CNY, with the turnover rate declining, indicating reduced market activity[5] - The proportion of stocks rising increased to 54.77%, with the median weekly return for A-share stocks rising to 0.6%[5] Fund Flows - New issuance of equity funds decreased to 21.84 billion CNY, while foreign capital inflow accelerated, with a net inflow of 8.0 million USD as of November 5[6] - The net buying amount of financing decreased to 11.63 billion CNY, accounting for 10.8% of total trading volume[6] Sector Performance - Foreign capital primarily flowed into the electronics sector, with a net inflow of 63.2 million USD, while financing capital mainly flowed into the power equipment sector, with a net inflow of 68.3 billion CNY[7] - The healthcare equipment sector is expected to benefit from policy-driven market recovery, with significant growth in bidding volumes for new medical equipment[17][20] Economic Indicators - The average price of Brent crude oil was 68.17 USD per barrel in Q3 2025, reflecting a year-on-year decrease of 13.40%[44] - The construction sector showed signs of recovery, with new home transaction areas in major cities decreasing by 40.6% week-on-week, indicating ongoing challenges in the real estate market[33] Investment Recommendations - The company recommends an overweight position in A/H shares and industrial commodities, suggesting an equity allocation of 45% and a commodity allocation of 10%[9][10]

马应龙药业集团股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 11 月 2025 年第一次临时股东大会会议资料 三、股东发言应举手示意，并按照会议的安排进行。 四、会议进行中接受股东（或其授权代表）发言或提问。股东每 次发言或提问应围绕本次会议议题进行，简明扼要，时间不超过 3 分 钟。 五、股东要求发言时不得打断会议报告人的报告或其他股东的发 言，股东提问和发言不得超出本次会议议案范围。股东违反上述规定 的，大会主持人有权加以制止或拒绝。 六、未经公司董事会同意，任何人员不得摄像、录音、拍照。如 有违反，大会组织方有权加以制止。 马应龙药业集团股份有限公司 股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事 效率，保证股东大会的顺利进行，根据中国证监会《上市公司股东会 规则》、《公司章程》及有关法律法规的要求，特制订本须知。 一、董事会以维护全体股东的合法权益、确保大会正常秩序和议 事效率为原则，认真履行《公司章程》中规定的职责。 二、股东参加股东大会依法享有发言权、质询权、表决权等权利。 股东参加股东大会履行其法定义务，不得侵犯其他股东的合法权益。 2 / 79 ...

Core Viewpoint - The article emphasizes the importance of early eye care and the effectiveness of using eye creams to prevent and reduce wrinkles, particularly highlighting a specific product from the brand Ma Ying Long, which is known for its history in eye care and recent innovations in eye cream formulations [7][16][34]. Group 1: Product Effectiveness - The article discusses the benefits of consistent use of eye cream, citing a case where a user maintained youthful skin around the eyes for over 20 years [9][12]. - The Ma Ying Long "Tonghua Oat Peptide Anti-Wrinkle Eye Cream" is highlighted for its professional formulation aimed at anti-wrinkle, firming, and moisturizing effects, supported by a report showing its ability to promote protein synthesis [42][44]. - The product is noted for its affordability, with a promotional price of 99 yuan for a combination of products, making it a cost-effective option compared to international brands [52][94]. Group 2: Brand Background - Ma Ying Long has a long history in the eye care industry, dating back to 1582, originally focusing on eye medications before expanding into other areas [21][22]. - The brand gained popularity with its hemorrhoid cream but is now refocusing on eye care products, leveraging its historical expertise [27][34]. - The "Tonghua" brand under Ma Ying Long is a testament to its commitment to eye care, developed in collaboration with various universities and research institutions [34][36]. Group 3: Ingredients and Technology - The eye cream features a combination of active ingredients, including Oat Peptide, which is noted for its strong absorption and effectiveness compared to synthetic peptides [56][59]. - The formulation also includes proprietary extracts from traditional Chinese medicine, enhancing its efficacy in addressing eye area concerns [60][64]. - The product is designed to improve skin hydration and elasticity, addressing issues like dryness and puffiness around the eyes [74][77].

Core Insights - Hainan Wide Ze Technology Co., Ltd. has been established, focusing on manufacturing and sales of home textiles and first-class medical devices [1][2] - The company is co-owned by Mayinglong Pharmaceutical Group Co., Ltd. and Wuhan Tianyi Medical Technology Investment Co., Ltd. [1][3] Company Information - The legal representative of Hainan Wide Ze Technology Co., Ltd. is Chen Xin [2] - The registered capital of the company is 5 million yuan [2] - The company is located in Haikou City, Hainan Province, with a business license valid until November 3, 2025 [2] Shareholding Structure - Mayinglong Pharmaceutical Group Co., Ltd. holds a 70% stake in Hainan Wide Ze Technology Co., Ltd. [3] - Wuhan Tianyi Medical Technology Investment Co., Ltd. owns the remaining 30% [3]

Core Insights - Hainan Guangweize Technology Co., Ltd. has been established, focusing on manufacturing and sales of household textiles, industrial textiles, and Class I medical devices [1] Company Overview - The company is co-owned by Mayinglong (600993) and its subsidiary Wuhan Tianyi Pharmaceutical Technology Investment Co., Ltd. [1]

Core Insights - The release of the "2025 Perianal Microecological Health Management White Paper" by Mayinglong and CBNData aims to promote awareness of perianal health and shift management from passive to proactive approaches [1][4] - The white paper highlights the high prevalence of anal diseases in China, with a 50.1% incidence rate among adults, and emphasizes the need for authoritative health education to address misconceptions and low intervention rates [2][3] Group 1: Market Demand and Structure - The white paper indicates that 64.8% of patients with anal diseases do not seek treatment until symptoms become unbearable, reflecting a significant gap in early intervention [2][3] - The market for hemorrhoid medications in retail and hospital settings is approximately 2.321 billion yuan and 1.403 billion yuan respectively, indicating a stable market with potential for growth due to lifestyle changes [2][3] - The demand for anal health products is driven by modern sedentary lifestyles, with high-risk groups including drivers, teachers, and office workers, as well as an increase in incidence with age [2][3] Group 2: Product and Service Gaps - The current market is primarily focused on treatment products like hemorrhoid ointments, with a lack of preventive and health care products, indicating unmet structural demand [3][4] - Mayinglong's expansion into health products, such as hygiene wipes, is rapidly growing, with sales expected to exceed 100 million yuan in 2024, highlighting a shift towards a more comprehensive health management approach [3][10] Group 3: Theoretical Framework and Health Management - The white paper introduces the "perianal microecology" theory, which emphasizes the importance of microbial balance and its role in health, providing a scientific basis for understanding disease mechanisms [4][9] - The theory suggests that anal diseases are modern lifestyle diseases that affect various demographics, challenging traditional beliefs about their causes and providing a framework for targeted interventions [4][9] Group 4: Strategic Positioning and Future Directions - Mayinglong's strategy focuses on comprehensive health management across the entire lifecycle, moving from a product-centric approach to a service-oriented model that includes prevention, care, diagnosis, treatment, and rehabilitation [9][10] - The company aims to reshape health concepts and participate in industry standard-setting, aligning with broader trends in the healthcare industry towards quality and holistic health management [10][20]

Core Viewpoint - Ma Yinglong is a leading company in the field of anorectal health in China, with a strong brand and unique pharmaceutical techniques, focusing on drug manufacturing, retail, wholesale, and medical services [1] Group 1: Business Performance - For Q3 2025, Ma Yinglong reported revenue of 2.837 billion yuan, ranking 20th among 69 companies in the industry, while the industry leader, Baiyunshan, had revenue of 61.606 billion yuan [2] - The net profit for the same period was 519 million yuan, placing the company 16th in the industry, with the top performer, Yunnan Baiyao, achieving 4.789 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Ma Yinglong's debt-to-asset ratio was 17.03%, down from 19.40% year-on-year and significantly lower than the industry average of 32.81%, indicating strong solvency [3] - The gross profit margin for the same period was 49.09%, an increase from 47.77% year-on-year, but slightly below the industry average of 52.44% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 23.06% to 38,300, while the average number of circulating A-shares held per shareholder decreased by 18.74% to 11,200 [5] - New major shareholders include two funds, with significant holdings, while some previous major shareholders reduced their stakes [5] Group 4: Business Highlights and Future Outlook - Ma Yinglong's performance in H1 2025 was strong, with a notable increase in profitability and cash flow, driven by a more than 7% revenue growth in hemorrhoid treatments and rapid expansion in hygiene and beauty products [6] - The company is expected to achieve net profits of 617 million yuan, 731 million yuan, and 838 million yuan from 2025 to 2027, reflecting growth rates of 16.9%, 18.4%, and 14.6% respectively [6]

Core Points - The company will hold its first extraordinary general meeting of 2025 on November 20, 2025 [3][23] - The meeting will be conducted using a combination of on-site and online voting methods [3][4] - The company plans to revise its articles of association, including the cancellation of the supervisory board [18][21] Meeting Details - Meeting Date and Time: November 20, 2025, at 15:15 [3] - Location: Company conference room [3] - Online Voting System: Shanghai Stock Exchange's online voting system [3] - Voting Time: November 20, 2025, from 9:15 to 15:00 [3] Voting Procedures - Shareholders can vote through the trading system or the internet voting platform [4][6] - Multiple accounts held by a shareholder can be combined for voting rights [6] - Duplicate votes through different methods will be counted as the first vote [7] Attendance - Shareholders registered by the close of trading on the registration date are eligible to attend [8] - Company directors, supervisors, and senior management will also attend [9][10] Registration Method - Registration for attendance must be completed by November 13, 2025 [12] - Registration can be done in person or via mail [12] Other Matters - The meeting will last half a day, and attendees are responsible for their own travel and accommodation costs [12]

Core Viewpoint - The company announced the cancellation of its supervisory board and the revision of its articles of association to optimize its governance structure and enhance governance efficiency [8][9]. Financial Data - The financial statements for the third quarter are unaudited, and the company has provided key financial data and indicators in RMB [3][7]. - The report indicates that there were no significant changes in the financial indicators or major accounting data during the reporting period [5]. Corporate Governance Changes - The company plans to abolish the supervisory board and has proposed amendments to its articles of association, which will be submitted for approval at the shareholders' meeting [8]. - The company has also revised and formulated certain governance systems to ensure compliance with relevant laws and regulations [9].

Group 1 - The company, Mayinglong (SH 600993), announced its 11th 22nd board meeting held on October 28, 2025, via telecommunication, where the "2025 Q3 Report" and other documents were reviewed [1] - For the first half of 2025, the revenue composition of Mayinglong was as follows: pharmaceutical manufacturing accounted for 62.47%, pharmaceutical commerce for 30.62%, and hospital diagnosis and treatment for 10.65%, with undistributed amounts at 0.23% and internal offsets at -3.98% [1] - As of the report date, Mayinglong's market capitalization stood at 11.7 billion yuan [1]